Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Tax Provisions (2023 - 2025)

Krystal Biotech's Tax Provisions history spans 3 years, with the latest figure at -$260000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions fell 108.3% year-over-year to -$260000.0; the TTM value through Dec 2025 reached -$15.4 million, down 347.86%, while the annual FY2025 figure was -$15.4 million, 347.86% down from the prior year.
  • Tax Provisions for Q4 2025 was -$260000.0 at Krystal Biotech, up from -$31.4 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $8.4 million in Q2 2025 and bottomed at -$31.4 million in Q3 2025.
  • The 3-year median for Tax Provisions is $2.3 million (2023), against an average of -$899750.0.
  • The largest YoY upside for Tax Provisions was 1669.6% in 2025 against a maximum downside of 1313.02% in 2025.
  • A 3-year view of Tax Provisions shows it stood at $2.0 million in 2023, then surged by 59.34% to $3.1 million in 2024, then tumbled by 108.3% to -$260000.0 in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Tax Provisions are -$260000.0 (Q4 2025), -$31.4 million (Q3 2025), and $8.4 million (Q2 2025).